Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| BI-847325 | BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Group: Pharmaceutical. Alternative Names: BI-847325; BI 847325; BI847325. CAS No. 1207293-36-4. Pack Sizes: 10 mg. Product ID: B0084-470824. Molecular formula: C29H28N4O2. Mole weight: 464.56. Custom synthesis is available. Send your inquiries for more information. |  London |
| Binimetinib | Binimetinib is an oral, highly selective MEK inhibitor. Group: Pharmaceutical. Alternative Names: MEK162; MEK-162; MEK 162; ARRY162; ARRY-162; ARRY 162; ARRY438162, Binimetinib; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. CAS No. 606143-89-9. Pack Sizes: 300 mg. Product ID: B0084-455720. Molecular formula: C17H15BrF2N4O3. Mole weight: 441.233. Custom synthesis is available. Send your inquiries for more information. | London |
| Cobimetinib | Cobimetinib (GDC-0973, RG7420) is a potent, orally available and highly selective MEK1 inhibitor with IC50 of 4.2 nM. It shows more than 100-fold selectively for MEK1 over MEK2 when tested against a panel of more than 100 serine-threonine and tyrosine kinases and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Group: Pharmaceutical. Alternative Names: XL518; GDC-0973; RG7420. CAS No. 934660-93-2. Pack Sizes: 25 mg. Product ID: B0084-460683. Molecular formula: C21H21F3IN3O2. Mole weight: 531.31. Custom synthesis is available. Send your inquiries for more information. | London |
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Group: Pharmaceutical. Alternative Names: LGX818; LGX-818; LGX 818; Methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate. CAS No. 1269440-17-6. Pack Sizes: 150 mg. Product ID: B0084-462563. Molecular formula: C22H27ClFN7O4S. Mole weight: 540.011. Custom synthesis is available. Send your inquiries for more information. | London |
| PD0325901 | PD-0325901 is a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. Uses: Reprogramming, self-renewal. Group: Pharmaceutical. Alternative Names: PD 0325901; PD 325901. CAS No. 391210-10-9. Pack Sizes: 100 mg. Product ID: B0084-091588. Molecular formula: C16H14F3IN2O4. Mole weight: 482.198. Custom synthesis is available. Send your inquiries for more information. | London |
| RGB-286638 Free base | RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated equimolar (50nM) activity in freshly isolated tumor cells from MM patients, while manifesting less cytotoxicity in healthy donor PBMCs. It reduced the phosphorylation of Rb at S807/811 in MM.1S and MM.1R cells, but had no effects on p-Rb S780. Group: Pharmaceutical. Alternative Names: 1-[3-[4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-4-oxo-1H-indeno[1,2-c]pyrazol-5-yl]-3-morpholin-4-ylurea; RGB 286638; RGB286638. CAS No. 784210-88-4. Pack Sizes: 100 mg. Product ID: B0084-463330. Molecular formula: C29H35N7O4. Mole weight: 545.63. Custom synthesis is available. Send your inquiries for more information. | London |
| Thiazovivin | Thiazovivin is a selective, cell permeable small molecule that directly targets Rho-associated kinase (ROCK). In addition, Thiazovivin protects human embryonic stem cells (hESCs) in the absence of ECM by regulating E-cadherin mediated cell-cell interaction. This observation suggests that Thiazovivin promotes cell survival. In other studies Thiazovivin, in combination with inhibitors of the TGF-β receptor and MEK pathway, has shown to improve reprogramming efficiency by more than 200-fold. Uses: Reprogramming, self-renewal. Group: Pharmaceutical. Alternative Names: N-benzyl-2-(pyrimidin-4-ylamino)thiazole-4-carboxamide; N-Benzyl-2-(pyrimidin-4-ylamino)-thiazole-4-carboxamide; N-(PHENYLMETHYL)-2-(4-PYRIMIDINYLAMINO)-4-THIAZOLECARBOXAMIDE; N-Benzyl-[2-(pyrimidin-4-yl)amino]thiazole-4-carboxamide; 4-THIAZOLECARBOXAMIDE, N-(PHENYLMETHYL)-2-(4-PYRIMIDINYLAMINO)-. CAS No. 1226056-71-8. Pack Sizes: 25 mg. Product ID: B0084-286727. Molecular formula: C15H13N5OS. Mole weight: 311.363. Custom synthesis is available. Send your inquiries for more information. | London |
| Trametinib | A MEK inhibitor that suppresses MEK1 and MEK2 with IC50 of 0.92 and 1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. It has been approved by FDA, in combination with Tafilnar, for the treatment of metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation. Group: Pharmaceutical. Alternative Names: GSK-1120212; GSK 1120212; GSK1120212; JTP74057; JTP 74057; JTP-74057; Mekinist. CAS No. 871700-17-3. Pack Sizes: 500 mg. Product ID: B0084-307744. Molecular formula: C26H23FIN5O4. Mole weight: 615.39. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
